Anti-metastatic effect of 131I-labeled Buthus martensii Karsch chlorotoxin in gliomas

Wu,Shan; Ma,Ke; Qiao,Wen‑Li; Zhao,Ling‑Zhou; Liu,Chang‑Cun; Guo,Li‑Lei; Xing,Yan; Zhu,Mei‑Lin; Zhao,Jin‑Hua

doi:10.3892/ijmm.2018.3905

Anti-metastatic effect of 131I-labeled Buthus martensii Karsch chlorotoxin in gliomas

Authors:
- Shan Wu
- Ke Ma
- Wen‑Li Qiao
- Ling‑Zhou Zhao
- Chang‑Cun Liu
- Li‑Lei Guo
- Yan Xing
- Mei‑Lin Zhu
- Jin‑Hua Zhao
View Affiliations

Affiliations: Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P.R. China, Shandong Co‑Innovation Center of Classic TCM formula, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China, Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P.R. China, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China
Published online on: October 1, 2018 https://doi.org/10.3892/ijmm.2018.3905
Pages: 3386-3394
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the underlying molecular mechanism by which Buthus martensii Karsch chlorotoxin (BmK CT) inhibits the invasion and metastasis of glioma cells and the possibility of 131I‑labeled BmK CT (131I‑BmK CT) as a novel targeted agent for the treatment of glioma. The impact of BmK CT with and without 131I radiolabeling on the invasion and metastasis of glioma cells in vitro was studied. Cell viability was assessed using Cell Counting Kit‑8 and plate colony formation assays in order to confirm the cytotoxicity of BmK CT and 131I‑BmK CT at different concentrations. Transwell invasion and wound‑healing assays were conducted in order to investigate the inhibitory effects BmK CT and 131I‑BmK CT on cell migration and invasion. Furthermore, western blotting, ELISA immunofluorescence and a gelatin zymography assay were performed to evaluate changes in the protein expression levels of glioma cells following treatment with BmK CT or 131I‑BmK CT. The results indicated that BmK CT inhibits the invasion and metastasis of glioma cells via regulation of tissue inhibitor of metalloproteinase‑2 expression and that 131I‑BmK CT has the potential to be a novel targeted therapeutic drug for glioma.

View Figures

View References

1	Goodenberger ML and Jenkins RB: Genetics of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
2	Cuddapah VA, Robel S, Watkins S and Sontheimer H: A neuro-centric perspective on glioma invasion. Nat Rev Neurosci. 15:455–465. 2014. View Article : Google Scholar : PubMed/NCBI
3	Franceschi E, Tosoni A, Girardi F and Brandes AA: Bevacizumab in brain tumors: Ready for primetime. Future Oncol. 5:1183–1184. 2009. View Article : Google Scholar : PubMed/NCBI
4	Yu Z, Zhao G, Zhang Z, Li Y, Chen Y, Wang N, Zhao Z and Xie G: Efficacy and safety of bevacizumab for the treatment of glioblastoma. Exp Ther Med. 11:371–380. 2016. View Article : Google Scholar : PubMed/NCBI
5	Hou LC, Veeravagu A, Hsu AR and Tse VC: Recurrent glioblastoma multiforme: A review of natural history and management options. Neurosurg Focus. 20:E52006. View Article : Google Scholar : PubMed/NCBI
6	Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
7	Fidler IJ, Kim SJ and Langley RR: The role of the organ micro-environment in the biology and therapy of cancer metastasis. J Cell Biochem. 101:927–936. 2007. View Article : Google Scholar
8	Stetler-Stevenson WG: Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol. 148:1345–1350. 1996.PubMed/NCBI
9	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
10	Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID and Sogayar MC: Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer. 9:202009. View Article : Google Scholar : PubMed/NCBI
11	Shimoda M, Jackson HW and Khokha R: Tumor suppression by stromal TIMPs. Mol Cell Oncol. 3:e9750822016. View Article : Google Scholar : PubMed/NCBI
12	Groblewska M, Siewko M, Mroczko B and Szmitkowski M: The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol. 50:12–19. 2012. View Article : Google Scholar : PubMed/NCBI
13	DeBin JA and Strichartz GR: Chloride channel inhibition by the venom of the scorpion Leiurus quinquestriatus. Toxicon. 29:1403–1408. 1991. View Article : Google Scholar : PubMed/NCBI
14	Lyons SA, O'Neal J and Sontheimer H: Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia. 39:162–173. 2002. View Article : Google Scholar : PubMed/NCBI
15	Deshane J, Garner CC and Sontheimer H: Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem. 278:4135–4144. 2003. View Article : Google Scholar
16	Soroceanu L, Gillespie Y, Khazaeli MB and Sontheimer H: Use of chlorotoxin for targeting of primary brain tumors. Cancer Res. 58:4871–4879. 1998.PubMed/NCBI
17	Hockaday DC, Shen S, Fiveash J, Raubitschek A, Colcher D, Liu A, Alvarez V and Mamelak AN: Imaging glioma extent with ¹³¹I-TM-601. J Nucl Med. 46:580–586. 2005.PubMed/NCBI
18	Shen S, Khazaeli M, Gillespie GY and Alvarez VL: Radiation dosimetry of ¹³¹I-chlorotoxin for targeted radiotherapy in glioma-bearing mice. J Neurooncol. 71:113–119. 2005. View Article : Google Scholar : PubMed/NCBI
19	Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, et al: Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol. 24:3644–3650. 2006. View Article : Google Scholar : PubMed/NCBI
20	Cheng YJ, Zhao JH, Qiao WL and Chen K: Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates. Am J Nucl Med Mol Imaging. 4:385–405. 2014.PubMed/NCBI
21	Fan S, Sun Z, Jiang D, Dai C, Ma Y, Zhao Z, Liu H, Wu Y, Cao Z and Li W: BmKCT toxin inhibits glioma proliferation and tumor metastasis. Cancer Lett. 291:158–166. 2010. View Article : Google Scholar
22	Zhao JH, Qiao WL, Zhang Y and Shao X: Preparation and in vitro evaluation of ¹³¹I-BmK CT as a glioma-targeted agent. Cancer Biother Radiopharm. 25:353–359. 2010. View Article : Google Scholar : PubMed/NCBI
23	Qiao WL, Zhao JH, Shao X, Zhang Z, Liu X, Wang T, Jin W and Yao Y: Preparation of ¹³¹I-BmK CT and bio-distribution and imaging in glioma-bearing rats. Nucl Tech. 34:213–216. 2011.
24	Fu YJ, Yin LT, Liang AH, Zhang CF, Wang W, Chai BF, Yang JY and Fan XJ: Therapeutic potential of chlorotoxin-like neurotoxin from the Chinese scorpion for human gliomas. Neurosci Lett. 412:62–67. 2007. View Article : Google Scholar
25	Fu YJ, An N, Chan KG, Wu YB, Zheng SH and Liang AH: A model of BmK CT in inhibiting glioma cell migration via matrix metalloproteinase-2 from experimental and molecular dynamics simulation study. Biotechnol Lett. 33:1309–1317. 2011. View Article : Google Scholar : PubMed/NCBI
26	Steeg PS: Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med. 12:895–904. 2006. View Article : Google Scholar : PubMed/NCBI
27	Mignatti P and Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 73:161–195. 1993. View Article : Google Scholar : PubMed/NCBI
28	Sternlicht MD and Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 17:463–516. 2001. View Article : Google Scholar : PubMed/NCBI
29	Kim SK, Kang SW, Park HJ, Ban JY, Oh CH, Chung JH, Oh IH, Cho KB and Park MS: Meta-analysis of association of the matrix metalloproteinase 2 (-735 C/T) polymorphism with cancer risk. Int J Clin Exp Med. 8:17096–17101. 2015.
30	Schulz R: Intracellular targets of matrix metalloproteinase-2 in cardiac disease: Rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol. 47:211–242. 2007. View Article : Google Scholar
31	Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG and Albini A: TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer. 75:246–253. 1998. View Article : Google Scholar : PubMed/NCBI
32	Su Y, Wan D and Song W: Dryofragin inhibits the migration and invasion of human osteosarcoma U2OS cells by suppressing MMP-2/9 and elevating TIMP-1/2 through PI3K/AKT and p38 MAPK signaling pathways. Anticancer Drugs. 27:660–668. 2016. View Article : Google Scholar : PubMed/NCBI
33	Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz C, et al: Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 366:1663–1673. 2012. View Article : Google Scholar : PubMed/NCBI
34	Gruenwald F and Ezziddin S: ¹³¹I-Metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 40:153–163. 2010. View Article : Google Scholar
35	Klutz K, Schaffert D, Willhauck MJ, Gruenwald GK, Haase R, Wunderlich N, Zach C, Gildehaus FJ, Senekowitsch-Schmidtke R, Goeke B, et al: Epidermal growth factor receptor-targeted ¹³¹I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Mol Ther. 19:676–685. 2011. View Article : Google Scholar : PubMed/NCBI
36	Kayano D and Kinuya S: Current consensus on I-131 MIBG therapy. Nucl Med Mol Imaging. 52:254–265. 2018. View Article : Google Scholar : PubMed/NCBI
37	Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ and Larson SM: Patient-specific dosimetry for ¹³¹I thyroid cancer therapy using ¹²⁴I PET and 3- dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 45:1366–1372. 2004.PubMed/NCBI
38	Zhang X, Liu DS, Luan ZS, Zhang F, Liu XH, Zhou W, Zhong SF and Lai H: Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature. Clin Transl Oncol. 20:928–935. 2018. View Article : Google Scholar :
39	Hosseinimehr SJ: Flavonoids and genomic instability induced by ionizing radiation. Drug Discov Today. 15:907–18. 2010. View Article : Google Scholar : PubMed/NCBI
40	Leo M, Sabini E, Ionni I, Sframeli A, Mazzi B, Menconi F, Molinaro E, Bianchi F, Brozzi F, Santini P, et al: Use of low-dose radioiodine ablation for Graves' orbitopathy: Results of a pilot, perspective study in a small series of patients. J Endocrinol Invest. 41:357–361. 2018. View Article : Google Scholar
41	Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S and Madeddu G: ¹³¹I SPECT/CT in the follow-up of differentiated thyroid carcinoma: Incremental value versus planar imaging. J Nucl Med. 50:184–90. 2009. View Article : Google Scholar : PubMed/NCBI